
Piramal Pharma is a pharmaceutical company combining contract development and manufacturing, inhaled-anesthetic hospital generics, and Indian consumer self-care brands.
piramalpharma.comCrawled Nov 15, 2026
Piramal Pharma's partnership with AbbVie offers therapeutic development and medicines for glaucoma, dry eye, infections and inflammation.
Explore Piramal Consumer Healthcare brands in skincare, wellness, pain relief and personal care designed to support everyday health.
Piramal Critical Care (PCC), a division of PPL, is a global leader in inhaled anesthetics and hospital generics for critical care worldwide.
Learn how to select the right pharma company for outsourcing across the USA, Canada, and UK, from pharma services to drug discovery process expertise.
Understand GMP compliance requirements in the US, UK, and Canada to enhance pharma manufacturing, drug development, and product quality.
Read Piramal Pharma blogs on CDMO, drug development, manufacturing, supply chain, quality, sustainability and careers in the pharmaceutical industry.
The page explains how pharma manufacturing, drug discovery, and pharmaceutical development adapt to regulations in the United States, United Kingdom, and Canada.
Discover Piramal Pharma Investors Day details including management attendees, key presentations, and business strategy updates.
The page provides updates on Piramal Pharma’s news and media coverage, including leadership views and industry insights.
Watch Piramal Pharma videos showcasing company updates, leadership messages, corporate stories, key highlights and insights shaping global healthcare
Piramal Pharma Limited offers career opportunities in healthcare and global impact-driven roles.
The page introduces Piramal Pharma’s Board of Directors, which provides strategic vision and industry expertise for healthcare solutions.
The page presents Piramal Pharma’s management team, including the Chairperson and CEO, who lead strategy and innovation across its businesses.
Piramal Pharma Limited operates as a global pharmaceutical manufacturer delivering services and healthcare products worldwide.
Piramal Pharma Limited outlines its purpose, values, leadership, businesses, and commitment to quality in global pharmaceutical manufacturing.
The page connects users with Piramal Pharma’s investor relations team for shareholder and financial inquiries.
Contact Piramal Pharma Limited for business inquiries, partnerships, investor relations, career opportunities and general information
Piramal Pharma is a global pharmaceutical company offering CDMO services, critical care and consumer healthcare products worldwide.
Piramal Pharma’s Privacy Policy, effective August 28, 2023, explains how it protects personal information and privacy rights.
Piramal Pharma reports a return to profitability in Q2 FY27 after a first-half loss. The company raises its FY27 revenue growth outlook while targeting **$2 billion in revenue and a 25% EBITDA margin by FY30**. Leadership expresses confidence in sustained financial improvement.
Oct 2026financialexpress.comNews article
Piramal Pharma projects **19-20% full-year revenue growth** in FY27, driven by its **CDMO (contract development and manufacturing) and complex hospital generics** segments. The company reports strong first-half performance and maintains its guidance to sustain growth in the second half. Chairperson **Nandini Piramal** highlights broad-based expansion across its three core businesses while targeting improved profitability.
Oct 2026CNBCTV18News article
Piramal Pharma raises its growth guidance to **19–20%** for the year, projecting a stronger second half driven by **increased orders and market gains**. The company cites a **stable outlook** as it pursues expansion amid robust demand. Leadership attributes confidence to operational momentum and favorable market conditions.
Oct 2026BusinessLineNews article
Piramal Pharma reduces reliance on Chinese raw materials to mitigate supply chain risks. The company, which generates over half its revenue from contract manufacturing, cites global turmoil—particularly in West Asia—as a key concern. This strategic shift aims to strengthen operational resilience amid geopolitical and economic uncertainties.
Oct 2026business-standard.comNews article